More on Multiple Myeloma From ASCO 2023 Focus on Bispecific ...

BCMA-Targeted Bispecific Antibodies in Relapsed ... - PeerVoice

So now, let's focus on bispecific antibodies and how they work for the treatment of multiple myeloma. Normal antibodies are made of two identical heavy ...

ASCO 2024 preview – more questions for BioNTech | ApexOnco

BioNTech needs its cancer projects to pick up the Covid slack, but data on two bispecific antibody projects, acasunlimab and PM8002, are far from emphatic.

From Bench to Bedside: New Frontiers in Multiple Myeloma

In October 2022, the FDA granted accelerated approval to teclistamab-cqyv (Tecvayli), the first bispecific antibody targeting BCMA. Like the CAR ...

ASCO24: Sanofi Reports Sarclisa Combo's Fatality Reduction in ...

Sanofi announced on Monday at the ASCO annual meeting that a combination treatment that includes its anti-CD38 monoclonal antibody Sarclisa had ...

Immunotherapy for multiple myeloma: new chances and hope

Daratumumab has been included in first-line therapy for NDMM. Isatuximab, another IgG1-κ chimeric monoclonal antibody with a mechanism of action ...

A Focus on CAR T-Cell Therapy and Bispecific Antibodies in ...

While many drug combinations are currently approved for use in patients with relapsed and/or refractory multiple myeloma who have progressed on multiple lines ...

FDA Approves 2 New Bispecifics for Relapsed or Refractory Multiple ...

Patients with relapsed or refractory multiple myeloma have new treatment options after the U.S. Food and Drug Administration granted ...

Multiple Myeloma in 2023 Ways: From Trials to Real Life - MDPI

Bispecific antibodies represent an off-the-shelf therapy that can be extremely beneficial for those heavily pretreated patients with rapidly progressive disease ...

Multiple Myeloma Video Perspectives - Healio

Healio spoke with experts about recent advancements in multiple myeloma, the treatment pipeline, common comorbidities and more.

Talquetamab Combo Updates Show Durable Responses in Heavily ...

Talquetamab (Talvey; Johnson & Johnson) was approved August 8, 2023, by FDA for the treatment of relapsed or refractory multiple myeloma in ...

Clinical evidence for immune-based strategies in early-line multiple ...

Almost all patients with multiple myeloma (MM) will eventually develop disease that has relapsed with or become refractory to available ...

Pfizer Highlights Progress in Accelerating Breakthrough Cancer ...

Pfizer will present data across its four tumor areas of focus at ASCO: breast cancer, genitourinary cancer, hematology-oncology and thoracic ...

News Release - Investor Relations | Regeneron Pharmaceuticals Inc.

Notably, new safety and efficacy results from a Phase 1/2 trial investigating the costimulatory bispecific antibody REGN7075 (EGFRxCD28) in ...

Bispecifics-Based Combination Therapy in Multiple Myeloma

This final of four exclusive episodes focuses on the combination of novel bispecific therapies and where they may fit into the treatment ...

Top News from Biggest Players at ASCO 2024 - Adelphi Research

... ASCO 2024, primarily focusing on lung, prostate, bladder and multiple myeloma. ... AMGEN FOCUSES ON NEW BISPECIFIC T-CELL ENGAGER IMDELLTRA.

Bispecific Antibodies for Multiple Myeloma: Six Things Your Patients ...

In 2022, the drug teclistamab became the first bispecific antibody to be approved by the U.S. Food and Drug Administration (FDA) for the ...

Teclistamab Shows 100% Response Rate in High-Risk Smoldering ...

Teclistamab-cqyv (Tecvayli), a bispecific antibody, led to significant activity when used as a treatment for patients with high-risk ...

European Commission Approves Reduced Dosing Frequency for ...

Teclistamab, the first BCMA-targeting bispecific antibody to receive approval in Europe, maintained deep and durable responses, with reduced onset of Grade ...

Encouraging safety and efficacy for REGN5459, a BCMA×CD3 ...

Dr Attaya Suvannasankha speaks to ecancer as part of AACR 2023 about her study looking at REGN5459, a BCMA×CD3 bispecific antibody with low CD3 affinity.

Safety and efficacy of T-cell-redirecting bispecific antibodies for ...

Multiple myeloma (MM) is the second most frequent hematological malignancy around the world [1]. The disease is characterized by the ...